Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus

Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus Publisher Pubmed

Urbanska AM¹ ; Ponnazhagan S² ; Mozafari M^{3, 4, 5, 6}

Show Affiliations

1. Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Medical Center, New York, NY, United States
2. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States
3. Bioengineering Research Group, Nanotechnology and Advanced Materials Department, Materials and Energy Research Center (MERC), Tehran, Iran
4. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
5. Department of Tissue Engineering and Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
6. Materials and Energy Research Center (MERC), Iran University of Medical Sciences, Tehran, Iran

Source: Cancer Research Published:2018

Abstract

Despite esophageal adenocarcinoma (EAC) being the most widespread among gastrointestinal cancers, with an 11-fold increase in the risk of cancer for patients with Barrett esophagus (BE), its prognosis is still poor. There is a critical need to better perceive the biology of cancer progression and identification of specific targets that are the hallmark of BE's progression. This review explores the established animal models of BE, including genetic, surgical and nonsurgical approaches, potential chemoprevention targets, and the reasoning behind their applications to prevent Barrett-related EAC. The key methodological features in the design feasibility of relevant studies are also discussed. ©2018 American Association for Cancer Research.

2. Current Status and Future Prospects for Esophageal Cancer, Cancers (2023)

3. The Association Between Waterpipe Smoking and Gastroesophageal Reflux Disease, International Journal of Epidemiology (2017)

Experts (# of related papers)

Reza Malekzadeh (2)

Hossein Poustchi (1)

Style	Citing Format
MLA	Urbanska AM, Ponnazhagan S, Mozafari M. "Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus." Cancer Research, vol. 78, no. 14, 2018, pp. 3747-3754.
APA	Urbanska AM, Ponnazhagan S, Mozafari M (2018). Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus. Cancer Research, 78(14), 3747-3754.
Chicago	Urbanska AM, Ponnazhagan S, Mozafari M. "Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus." Cancer Research 78, no. 14 (2018): 3747-3754.
Harvard	Urbanska AM, Ponnazhagan S, Mozafari M (2018) 'Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus', Cancer Research, 78(14), pp. 3747-3754.
Vancouver	Urbanska AM, Ponnazhagan S, Mozafari M. Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus. Cancer Research. 2018;78(14):3747-3754.
BibTex	@article{ author = {Urbanska AM and Ponnazhagan S and Mozafari M}, title = {Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus}, journal = {Cancer Research}, volume = {78}, number = {14}, pages = {3747-3754}, year = {2018} }
RIS	TY - JOUR AU - Urbanska AM AU - Ponnazhagan S AU - Mozafari M TI - Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus JO - Cancer Research VL - 78 IS - 14 SP - 3747 EP - 3754 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract